Association of baseline visual acuity and retinal thickness with 1-year efficacy of aflibercept, bevacizumab, and ranibizumab for diabetic macular edema

JAMA Ophthalmology

Volumn 134, Issue 2, 2016, Pages 127-134

  Wells, John A ^a   Glassman, Adam R ^b   Jampol, Lee M ^c   Aiello, Lloyd Paul ^d   Antoszyk, Andrew N ^e   Baker, Carl W ^f   Bressler, Neil M ^g,h   Browning, David J ^e   Connor, Crystal G ^b   Elman, Michael J ⁱ   Ferris, Frederick L ^j   Friedman, Scott M ^k   Melia, Michele ^b   Pieramici, Dante J ^l   Sun, Jennifer K ^d   Beck, Roy W ^b  

^a Palmetto Retina Center   (United States)

^b JAEB CENTER FOR HEALTH RESEARCH   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e Nose and Throat Associates   (United States)

^f Paducah Retinal Center   (United States)

^g JOHNS HOPKINS UNIVERSITY   (United States)

^h JAMA   (United States)

ⁱ Elman Retina Group   (United States)

^j NATIONAL EYE INSTITUTE   (United States)

^k Florida Retina Consultants   (United States)

^l California Retina Consultants   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; RANIBIZUMAB; ANGIOGENESIS INHIBITOR; HYBRID PROTEIN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR; VEGFA PROTEIN, HUMAN;

ADULT; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETIC MACULAR EDEMA; DISEASE ASSOCIATION; DRUG EFFICACY; HUMAN; LASER COAGULATION; MAJOR CLINICAL STUDY; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETINAL THICKNESS; VISUAL ACUITY; ANTAGONISTS AND INHIBITORS; DIABETIC RETINOPATHY; FEMALE; INTRAVITREAL DRUG ADMINISTRATION; MACULAR EDEMA; MALE; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; RETINA; TREATMENT OUTCOME;

ADULT; ANGIOGENESIS INHIBITORS; BEVACIZUMAB; DIABETIC RETINOPATHY; FEMALE; HUMANS; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MALE; MIDDLE AGED; RANIBIZUMAB; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; RETINA; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 84958526252     PISSN: 21686165     EISSN: 21686173     Source Type: Journal    
DOI: 10.1001/jamaophthalmol.2015.4599     Document Type: Article

References (3)

1. Wells JA, Glassman AR, Ayala AR, et al; Diabetic Retinopathy Clinical Research Network. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015;372(13):1193-1203.
2. Bressler SB, Edwards AR, Chalam KV, et al; Diabetic Retinopathy Clinical Research Network Writing Committee. Reproducibility of spectral-domain optical coherence tomography retinal thickness measurements and conversion to equivalent time-domain metrics in diabetic macular edema. JAMA Ophthalmol. 2014;132(9):1113-1122.
3. Spiegelman D, Hertzmark E. Easy SAS calculations for risk or prevalence ratios and differences. Am J Epidemiol. 2005;162(3):199-200.